According to a new report published by Allied Market Research, titled, “Bovine Mastitis Market," The bovine mastitis market was valued at $0.54 billion in 2021 and is estimated to reach $1.01 billion by 2031, growing at a CAGR of 6.3% from 2022 to 2031.

Mastitis in cows is one of the most prevalent illnesses affecting the dairy food industry. Bovine mastitis is an inflammation of the mammary gland in cattle due to injury or illness that results in abnormal and reduced milk output.

The increase in the prevalence of bovine mastitis and the rise in the incidence of cow injury drive the growth of the Bovine Mastitis Market Size. For instance, according to a research article published on August 2020, in Veterinary Medicine International, a publisher of original research articles and review articles in all areas of veterinary research, the overall prevalence of mastitis reported was 80% in Kenya. Bovine mastitis is mainly caused by various bacterial & fungal infections such as Pasteurella multocida, Staphylococcus aureus, Str. zooepidemicus, Str. agalactiae, Str. Pyogenes, Str. faecalis, and Aspergillus fumigatus.

Furthermore, the rise in the number of dairy farms and surge in the production of dairy products drive the growth of the Bovine Mastitis Market Size. The increase in demand for dairy products and an upsurge in milk production propel the growth of the Bovine Mastitis Industry. For instance, according to the United States Department of Agriculture (USDA’s) Milk Production report, the annual milk production in the U.S. in 2020 was 223 billion pounds, increasing just over 2% from the 218 billion pounds produced in 2019.

Moreover, Bovine Mastitis Market Trends that drive the growth of the bovine mastitis market include R&D for the development of bovine mastitis, an increase in product approvals, and new products launched in the Bovine Mastitis Industry. In addition, the integration of artificial intelligence (AI) with veterinary health and treatment further contributes to the growth of the market. In addition, increasing initiatives by government & non-government organizations and a rise in funding for veterinary care propels the growth of the market. For instance, in October 2020, NovaQuest Capital Management LLC, a leading investor in life sciences and healthcare, announced a $20 million (USD) product financing agreement with Mileutis Ltd., an Israeli biopharmaceutical company, to help mitigate the use of antibiotics on animals. NovaQuest’s investment is expected to drive the continued development and commercialization of Mileutis’ novel, biologically sourced, and residue-free therapies for animal health. Furthermore, the rise in concern for veterinary care and improvements in animal healthcare facilities in developing nations contribute to the growth of the Bovine Mastitis Market Forecast.

The bovine mastitis market is segmented into product, route of administration, end-user, and region.

On the basis of product, the market is divided into antibiotics and others. The antibiotics segment has the largest market share in 2021, and this trend is expected to continue during the Bovine Mastitis Market Analysis period, owing to new product launches and the high efficiency of antibiotics.

By route of administration, the market is categorized into intramammary and systemic. The systemic segment have the largest market share in 2021, and this trend is expected to continue during the forecast period, owing to an increase in product approvals and advancements in bovine mastitis treatment.

Depending on the end-user, the market is classified into veterinary hospitals & clinics and on-site treatment. The on-site treatment segment has the largest market share in 2021, and this trend is expected to continue during the forecast period, owing to growth in the dairy farm industry and a rise in the number of veterinarians.

Asia-Pacific accounted for a majority of the global bovine mastitis market share in 2021 and is anticipated to remain dominant during the forecast period. This is attributed to the large dairy industry and the presence of key players in the region. LAMEA is anticipated to witness lucrative growth, owing to the growing dairy industry and rise in demand for dairy products.

KEY FINDINGS OF THE STUDY

• On the basis of products, the antibiotics segment was the highest contributor to the market in 2021.
• Based on the route of administration, the systemic segment was the highest contributor to the market in 2021.
• Depending on the end user, the on-site treatment segment was the highest contributor to the market in 2021.
• Region-wise, Asia-Pacific garnered the largest revenue share in 2021, whereas LAMEA is anticipated to grow at the highest CAGR during the forecast period